CS
PCRX icon

Candriam SCA’s Pacira BioSciences PCRX Stock Holding History

Candriam SCA’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-181,901
Closed -$5.32M – 710
2024
Q1 		$5.32M Sell
181,901
-10,000
-5% -$307K 0.03% 331
2023
Q4 		$6.48M Buy
191,901
+40,000
+26% +$1.17M 0.04% 307
2023
Q3 		$4.66M Sell
151,901
-40,000
-21% -$1.44M 0.03% 316
2023
Q2 		$7.69M Buy
191,901
+12,000
+7% +$496K 0.06% 280
2023
Q1 		$6.76M Sell
179,901
-45,000
-20% -$1.79M 0.05% 310
2022
Q4 		$11.1M Buy
224,901
+45,000
+25% +$2.19M 0.07% 252
2022
Q3 		$9.57M Buy
179,901
+50,000
+38% +$2.78M 0.07% 282
2022
Q2 		$7.57M Sell
129,901
-44,180
-25% -$2.89M 0.06% 267
2022
Q1 		$13.3M Sell
174,081
-56,000
-24% -$3.73M 0.09% 214
2021
Q4 		$13.8M Buy
230,081
+25,121
+12% +$1.39M 0.09% 221
2021
Q3 		$11.5M Buy
+204,960
New +$11.8M 0.08% 251
2018
Q3 		– Sell
-44,440
Closed -$1.42M – 835
2018
Q2 		$1.42M Hold
44,440
– – 0.02% 547
2018
Q1 		$1.38M Sell
44,440
-2,560
-5% -$91.2K 0.02% 538
2017
Q4 		$2.15M Sell
47,000
-6,000
-11% -$238K 0.04% 437
2017
Q3 		$1.99M Hold
53,000
– – 0.03% 458
2017
Q2 		$2.53M Sell
53,000
-7,000
-12% -$325K 0.05% 418
2017
Q1 		$2.74M Buy
+60,000
New +$2.59M 0.05% 379
2015
Q1 		– Sell
-36,000
Closed -$3.19M – 654
2014
Q4 		$3.19M Buy
+36,000
New +$3.41M 0.07% 300

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's PCRX Position: Q2 2024 in Review

Candriam SCA sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 181,901 shares — an estimated $5.32M sold.

Candriam SCA first reported a position in PCRX in Q4 2014 and held it in 18 quarters. The position peaked at $13.8M in Q4 2021. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Candriam SCA reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 181,901 Pacira BioSciences shares in Q2 2024, an estimated $5.32M.
  • Candriam SCA first reported a position in Pacira BioSciences in Q4 2014 and held it in 18 quarters.
  • Candriam SCA's Pacira BioSciences position peaked at $13.8M in Q4 2021.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.